<DOC>
	<DOCNO>NCT02877199</DOCNO>
	<brief_summary>The hypothesis check whether baseline anti-E1E2 antibody correlate on-treatment viral kinetics could predict virological outcome treatment-experienced HCV-infected cirrhotic patient receive protease inhibitor-based triple therapy .</brief_summary>
	<brief_title>Anti-E1E2 Antibodies ( D32.10 Epitope-binding Antibodies ) HCV Triple Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>HCV patient compensate cirrhosis ( ChildPugh A ) HCV genotype 1 nonresponders previous course interferon ( IFN ) /ribavirin receive boceprevir telaprevir</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>anti-E1E2 antibody</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>triple therapy</keyword>
</DOC>